北京大学未来技术学院席建忠、上海交通大学附属胸科医院姜丽岩和北京大学未来技术学院叶步青研究组合作报道，患者源性肿瘤样细胞群为非小细胞肺癌个体化化疗和免疫治疗提供有力支持。2024年4月8日，国际知名学术期刊《细胞—干细胞杂志》发表了这一成果。

研究组报告了用于非小细胞肺癌(NSCLC)的患者源性肿瘤样细胞群(PTCs)，能够在10天内进行100 - 5000次药物试验。研究组建立了283个PTC模型，成功率为81%。PTCs包含由内源性间质细胞和免疫细胞自组装的原发肿瘤上皮，在表型和基因型特征上与原发肿瘤高度相似。

利用标准化培养和药物反应评估方案，PTC药物检测分析显示，在前瞻性预测临床结果方面，总体一致性为89%，区分完全/部分反应与进展性疾病的准确率为98.1%。值得注意的是，PTCs可以通过结合细胞活性和IFN-γ值评估来准确预测接受抗PD1治疗患者的临床结果。这些发现表明，PTCs可作为一种有价值的临床前模型，用于非小细胞肺癌的个性化治疗和基础研究。

据介绍，最近出现了许多患者来源的肿瘤模型。然而，它们指导个性化药物选择的潜力仍不清楚。

附：英文原文

Title: Patient-derived tumor-like cell clusters for personalized chemo- and immunotherapies in non-small cell lung cancer

Author: Shenyi Yin, Ying Yu, Nan Wu, Minglei Zhuo, Yanmin Wang, Yanjie Niu, Yiqian Ni, Fang Hu, Cuiming Ding, Hongsheng Liu, Xinghua Cheng, Jin Peng, Juan Li, Yang He, Jiaxin Li, Junyi Wang, Hanshuo Zhang, Xiaoyu Zhai, Bing Liu, Yaqi Wang, Shi Yan, Mailin Chen, Wenqing Li, Jincui Peng, Fei Peng, Ruibin Xi, Buqing Ye, Liyan Jiang, Jianzhong Jeff Xi

Issue&Volume: 2024-04-08

Abstract: Many patient-derived tumor models have emerged recently. However, their potentialto guide personalized drug selection remains unclear. Here, we report patient-derivedtumor-like cell clusters (PTCs) for non-small cell lung cancer (NSCLC), capable ofconducting 100–5,000 drug tests within 10 days. We have established 283 PTC modelswith an 81% success rate. PTCs contain primary tumor epithelium self-assembled withendogenous stromal and immune cells and show a high degree of similarity to the originaltumors in phenotypic and genotypic features. Utilizing standardized culture and drug-responseassessment protocols, PTC drug-testing assays reveal 89% overall consistency in prospectivelypredicting clinical outcomes, with 98.1% accuracy distinguishing complete/partialresponse from progressive disease. Notably, PTCs enable accurate prediction of clinicaloutcomes for patients undergoing anti-PD1 therapy by combining cell viability andIFN-γ value assessments. These findings suggest that PTCs could serve as a valuablepreclinical model for personalized medicine and basic research in NSCLC.

DOI: 10.1016/j.stem.2024.03.008

Source: https://www.cell.com/cell-stem-cell/abstract/S1934-5909(24)00090-0